IRMD carries no reported debt and holds a current ratio near 9.0 with equity of $106.5M against $14.6M in liabilities, suggesting minimal refinancing risk, though a large cash share of assets may flatter headline asset growth.
IRadimed Corporation (IRMD) balance sheet — 14-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Total Current Assets | 92.8M | 81.2M | 75.24M | 76M | 77.49M | 76.24M | 63.74M | 58.96M | 44.54M | 35.11M | 34.17M | 33.95M | 22.17M | 6.38M | 5M |
| Cash & Short-Term Investments | 63.29M | 51.16M | 52.23M | 49.76M | 57.96M | 62.5M | 51.98M | 46.25M | 34.38M | 26.34M | 25.68M | 26.97M | 17.37M | 2.71M | 1.95M |
| Cash Only | 63.29M | 51.16M | 52.23M | 49.76M | 57.96M | 62M | 50.07M | 43.48M | 28.03M | 18.21M | 17.71M | 19.37M | 9.45M | 2.46M | 1.7M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 501.86K | 1.91M | 2.77M | 6.35M | 8.14M | 7.97M | 7.6M | 7.91M | 246.2K | 250.79K |
| Accounts Receivable | 13.67M | 13.67M | 10.56M | 12.22M | 13.27M | 5.14M | 4.57M | 7.29M | 4.21M | 3.78M | 3.78M | 3.86M | 1.96M | 1.98M | 1.59M |
| Days Sales Outstanding | 55.1 | 59.52 | 52.61 | 68.06 | 90.9 | 44.84 | 52.65 | 69.11 | 50.48 | 59.76 | 42.41 | 44.64 | 45.71 | 63.8 | 75.3 |
| Inventory | 0 | 11.62M | 10.4M | 12.82M | 5.37M | 4.3M | 3.93M | 3.64M | 4.06M | 4.21M | 3.89M | 2.38M | 2.13M | 1.34M | 1.39M |
| Days Inventory Outstanding | 149.15 | 217.61 | 224.76 | 303.8 | 163.03 | 160.73 | 176.34 | 150.77 | 205.46 | 275.94 | 230.49 | 148.94 | 227.92 | 171.45 | 237.96 |
| Other Current Assets | 15.84M | 4.76M | 2.05M | 1.19M | 630.96K | 1M | 771.67K | 407.8K | 526.79K | 648.88K | 674.77K | 459.4K | 392.88K | 183.6K | 77.22K |
| Total Non-Current Assets | 28.27M | 27.57M | 23.08M | 16.15M | 8.02M | 6.64M | 7.33M | 7.77M | 3.9M | 3.9M | 3.03M | 1.29M | 1.14M | 602.6K | 557.41K |
| Property, Plant & Equipment | 24.08M | 23.86M | 16.97M | 11.33M | 4.61M | 4.55M | 4.84M | 5.01M | 1.87M | 1.87M | 1.46M | 905.62K | 794.84K | 327.34K | 265.62K |
| Fixed Asset Turnover | 3.71x | 3.51x | 4.32x | 5.79x | 11.57x | 9.19x | 6.56x | 7.69x | 16.28x | 12.35x | 22.32x | 34.89x | 19.69x | 34.64x | 28.93x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 3.41M | 3.38M | 3.1M | 2.52M | 2.07M | 1.12M | 960.88K | 860.09K | 832.52K | 885.5K | 918.71K | 175.51K | 250.84K | 267.02K | 276.03K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 782K | 239K | 198.91K | 181.45K | 648.67K | 201.32K | 261.99K | 232K | 109.76K | 200.2K | 173.82K | 124.19K | 19.68K | 8.23K | 3.24K |
| Total Assets | 121.07M | 108.78M | 98.33M | 92.16M | 85.51M | 82.88M | 71.07M | 66.73M | 48.44M | 39.01M | 37.19M | 35.24M | 23.31M | 6.99M | 5.55M |
| Asset Turnover | 0.78x | 0.77x | 0.74x | 0.71x | 0.62x | 0.50x | 0.45x | 0.58x | 0.63x | 0.59x | 0.87x | 0.90x | 0.67x | 1.62x | 1.38x |
| Asset Growth % | 36.62% | 10.63% | 6.69% | 7.77% | 3.18% | 16.63% | 6.5% | 37.75% | 24.17% | 4.89% | 5.53% | 51.2% | 233.62% | 25.79% | - |
| Total Current Liabilities | 10.32M | 10.18M | 8.51M | 16.33M | 8.55M | 6.82M | 4.92M | 5.86M | 4.69M | 4.08M | 3.66M | 2.9M | 2.28M | 1.45M | 2.33M |
| Accounts Payable | 2.42M | 1.82M | 1.9M | 1.86M | 1.8M | 782.9K | 657.05K | 993.74K | 772.47K | 656.72K | 1.12M | 1.01M | 629.17K | 427.47K | 408.42K |
| Days Payables Outstanding | 34.49 | 34.08 | 40.98 | 44 | 54.63 | 29.26 | 29.45 | 41.14 | 39.1 | 43.04 | 66.47 | 62.84 | 67.46 | 54.68 | 70.12 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.33K | 519.73K |
| Deferred Revenue (Current) | 13.31M | 2.87M | 2.26M | 2.57M | 3.37M | 2.55M | 1.95M | 1.67M | 1.8M | 1.62M | 1.03M | 536.92K | 308.34K | 207.4K | 389.4K |
| Other Current Liabilities | 3.78M | 457K | 268.27K | 367.46K | 94.03K | 255.31K | 236.49K | 190.18K | 315.94K | 278.61K | 280.63K | 64.77K | 93.72K | 12K | 64.94K |
| Current Ratio | 8.99x | 7.98x | 8.84x | 4.65x | 9.06x | 11.18x | 12.96x | 10.06x | 9.50x | 8.61x | 9.33x | 11.73x | 9.74x | 4.40x | 2.14x |
| Quick Ratio | 8.99x | 6.84x | 7.62x | 3.87x | 8.43x | 10.54x | 12.16x | 9.44x | 8.63x | 7.58x | 8.27x | 10.90x | 8.81x | 3.47x | 1.55x |
| Cash Conversion Cycle | 169.76 | 243.05 | 236.39 | 327.85 | 199.3 | 176.3 | 199.53 | 178.74 | 216.85 | 292.66 | 206.43 | 130.74 | 206.17 | 180.57 | 243.14 |
| Total Non-Current Liabilities | 4.29M | 3.98M | 2.99M | 4.41M | 3.29M | 3.88M | 4.76M | 5.35M | 1.81M | 2M | 1.64M | 415.78K | 142.9K | 111.76K | 2.66K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 1.42K | 1.62M | 1.91M | 2.21M | 2.46M | 2.72M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 374.25K | 0 | 54.09K | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 14.62M | 14.16M | 11.51M | 20.74M | 11.84M | 10.71M | 9.68M | 11.2M | 6.5M | 6.08M | 5.31M | 3.31M | 2.42M | 1.56M | 2.33M |
| Total Debt | 0 | 0 | 154.69K | 2.04M | 2.21M | 2.48M | 2.72M | 2.96M | 0 | 0 | 0 | 0 | 0 | 6.33K | 519.73K |
| Net Debt | -63.29M | -51.16M | -52.08M | -47.72M | -55.76M | -59.52M | -47.35M | -40.53M | -28.03M | -18.21M | -17.71M | -19.37M | -9.45M | -2.46M | -1.18M |
| Debt / Equity | 0.00x | - | 0.00x | 0.03x | 0.03x | 0.03x | 0.04x | 0.05x | - | - | - | - | - | 0.00x | 0.16x |
| Debt / EBITDA | 0.00x | - | 0.01x | 0.10x | 0.14x | 0.22x | 4.66x | 0.30x | - | - | - | - | - | 0.00x | 0.34x |
| Net Debt / EBITDA | -2.07x | -1.87x | -2.29x | -2.29x | -3.42x | -5.30x | -81.26x | -4.10x | -3.94x | -7.02x | -1.59x | -1.65x | -2.94x | -0.84x | -0.77x |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 106.45M | 94.62M | 86.82M | 71.42M | 73.67M | 72.17M | 61.38M | 55.52M | 41.95M | 32.93M | 31.89M | 31.93M | 20.89M | 5.42M | 3.22M |
| Equity Growth % | 34.51% | 8.98% | 21.56% | -3.06% | 2.08% | 17.58% | 10.55% | 32.37% | 27.38% | 3.27% | -0.14% | 52.86% | 285.24% | 68.4% | - |
| Book Value per Share | 8.27 | 7.36 | 6.79 | 5.61 | 5.83 | 5.73 | 4.93 | 4.52 | 3.46 | 2.81 | 2.66 | 2.54 | 2.04 | 0.52 | 0.31 |
| Total Shareholders' Equity | 106.45M | 94.62M | 86.82M | 71.42M | 73.67M | 72.17M | 61.38M | 55.52M | 41.95M | 32.93M | 31.89M | 31.93M | 20.89M | 5.42M | 3.22M |
| Common Stock | 1K | 1K | 1.27K | 1.26K | 1.26K | 1.25K | 1.23K | 1.18K | 1.1K | 1.06K | 1.07K | 1.12K | 1.08K | 700 | 700 |
| Retained Earnings | 74.1M | 64.23M | 56.79M | 43.26M | 47.26M | 46.99M | 37.67M | 36.3M | 26.67M | 20.36M | 19.87M | 12.66M | 5.13M | 3.07M | 1.14M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 17.01K | 37.09K | 30.37K | -42.19K | -48.91K | -36.85K | -55.28K | -21.47K | 924 | 7.15K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying IRMD stock.
As of 2025, IRadimed Corporation (IRMD) had total assets of $108.8M including $81.2M in current assets.
IRadimed Corporation (IRMD) carries total debt of $0.0M, offset by $51.2M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
IRadimed Corporation (IRMD) has total shareholders' equity (book value) of $94.6M ($7.36 book value per share). Book value represents the net worth of the company belonging to common stock holders.
IRadimed Corporation (IRMD) reported a current ratio of 7.98x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Quarterly earnings volatility under launch
Metrics are mathematically derived from official filings.
Equity Base Compounding Through Retained Earnings
Based on reported figures, IRMD's total equity expanded from $79.7M in Q2 2024 to $106.5M in Q3 2026, with retained earnings rising from $50.4M to $74.1M, indicating self-funded balance sheet strengthening over the period.
The steady climb in retained earnings, which accounts for most of the equity increase, suggests the business is internally funding its growth rather than relying on external capital. The quarter-over-quarter pattern is consistent rather than lumpy, which points to durable earnings generation instead of one-time gains. Investors should note that total assets grew at a similar pace, so the strengthening reflects accumulation of liquid resources rather than a balance sheet inflated by intangibles.
Cash Reserves Dominate Asset Base
As reported in financial statements, IRMD held $63.3M in cash in Q3 2026 against total liabilities of $14.6M, with the current ratio at 8.99, suggesting liquidity far exceeds near-term obligations.
A current ratio near 9 indicates the company could cover short-term liabilities many times over, which may provide substantial buffer against revenue shocks such as the Q2 2026 EPS miss. Cash has risen from $48.5M to $63.3M over the ten quarters, which appears to reflect retained cash flow rather than financing activity. The scale of idle liquidity may warrant monitoring for how management intends to deploy it, since large cash balances can dilute returns on equity.
Debt-Free Structure Limits Refinancing Exposure
According to recent SEC filings, IRMD's total debt declined from $371.8K in Q2 2024 to nil by Q3 2026, leaving a debt-to-equity ratio of effectively zero over the most recent quarters.
The complete retirement of borrowings suggests the company no longer carries refinancing or interest-rate risk, which removes a common source of balance sheet fragility in small-cap medical device companies. This structure implies that cash flow durability is not being partially committed to debt service. The conservative posture may also reflect limited need for external capital, which is consistent with the self-funded equity growth observed.
Deferred Revenue Tracks Service Contract Growth
Based on the supplied figures, deferred revenue rose from $5.3M in Q4 2024 to $7.9M in Q3 2026, a gain of roughly 49%, which may indicate growing recurring or service-linked obligations ahead of revenue recognition.
Deferred revenue growing faster than the broader revenue base could signal a rising share of prepaid service or extended warranty contracts, supporting the recurring-revenue thesis. However, the sequential movement is modest in absolute terms, so this should be read as a directional indicator rather than a strong forward guarantee. Investors should monitor whether deferred revenue continues to outpace reported revenue growth.
Goodwill-Free Assets Mask Asset Quality Questions
Based on reported figures, IRMD's net PP&E of $24.1M against total assets of $121.1M implies that a large share of the asset base is cash, which may make headline asset growth look stronger than the operating asset base warrants.
Because cash constitutes the majority of total assets, the reported asset expansion primarily reflects accumulated liquidity rather than productive capacity, which could flatter headline return-on-assets metrics. The absence of goodwill removes impairment risk, but it also means the company has not pursued acquisitions to broaden its platform. Investors should weigh whether the high cash share reflects disciplined capital management or limited reinvestment opportunities.